Literature DB >> 7528672

On the various manifestations of spontaneous autoimmune diabetes in rodent models.

S Degermann1, C Reilly, B Scott, L Ogata, H von Boehmer, D Lo.   

Abstract

Autoimmune (type 1) diabetes mellitus in mouse, rat, and humans shares several features, including T lymphocyte infiltration into pancreatic islets and a dependence on permissive class II major histocompatibility complex (MHC) alleles. We report here on an experimental model involving mice that express influenza hemagglutinin (HA) under the control of the insulin promoter and, at the same time, a transgenic class II MHC-restricted T cell receptor (TcR) specific for an HA peptide. These mice spontaneously develop islet infiltrates resembling those found in NOD mice and most animals become diabetic within 8 weeks of age. Because of the availability of a clonotypic TcR antibody, we can be confident that the Ins-HA transgene does not induce any measurable alterations in the vast majority of T cells with the transgenic TcR in primary and secondary lymphoid organs. Continuous export of large numbers of HA-specific lymphocytes from the thymus was not required for the manifestation of the disease since mice thymectomized at 3 days after birth still developed the disease albeit with smaller infiltrates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528672     DOI: 10.1002/eji.1830241236

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Immune regulation: susceptibility and resistance to autoimmunity.

Authors:  D Lo
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  CD4+ T cell mediated intestinal immunity: chronic inflammation versus immune regulation.

Authors:  A M Westendorf; M Templin; R Geffers; S Deppenmeier; A D Gruber; M Probst-Kepper; W Hansen; R S Liblau; F Gunzer; D Bruder; J Buer
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

3.  Defects in the Bcl-2-regulated apoptotic pathway lead to preferential increase of CD25 low Foxp3+ anergic CD4+ T cells.

Authors:  Yifan Zhan; Yuxia Zhang; Daniel Gray; Emma M Carrington; Philippe Bouillet; Hyun-Ja Ko; Lorraine O'Reilly; Ian P Wicks; Andreas Strasser; Andrew M Lew
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

Review 4.  Manipulating the type 1 vs type 2 balance in type 1 diabetes.

Authors:  Urs Christen; Matthias G von Herrath
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model.

Authors:  A Sarukhan; A Lanoue; A Franzke; N Brousse; J Buer; H von Boehmer
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

6.  TRPV1 properties in thoracic dorsal root ganglia neurons are modulated by intraperitoneal capsaicin administration in the late phase of type-1 autoimmune diabetes.

Authors:  Beatrice Mihaela Radu; Adina Daniela Iancu; Diana Ionela Dumitrescu; Maria Luisa Flonta; Mihai Radu
Journal:  Cell Mol Neurobiol       Date:  2012-10-31       Impact factor: 5.046

Review 7.  Checkpoints in the progression of autoimmune disease: lessons from diabetes models.

Authors:  I André; A Gonzalez; B Wang; J Katz; C Benoist; D Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

8.  Failure to censor forbidden clones of CD4 T cells in autoimmune diabetes.

Authors:  Sylvie Lesage; Suzanne B Hartley; Srinivas Akkaraju; Judith Wilson; Michelle Townsend; Christopher C Goodnow
Journal:  J Exp Med       Date:  2002-11-04       Impact factor: 14.307

9.  Rodent models for investigating the dysregulation of immune responses in type 1 diabetes.

Authors:  Feng-Cheng Chou; Heng-Yi Chen; Shyi-Jou Chen; Mei-Cho Fang; Huey-Kang Sytwu
Journal:  J Diabetes Res       Date:  2013-03-11       Impact factor: 4.011

10.  Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes.

Authors:  Irina Apostolou; Zhenyue Hao; Klaus Rajewsky; Harald von Boehmer
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.